[go: up one dir, main page]

MX2013005644A - Suministro local vascular de agonistas del receptor de adenosina a2a para reducir el daño al miocardio. - Google Patents

Suministro local vascular de agonistas del receptor de adenosina a2a para reducir el daño al miocardio.

Info

Publication number
MX2013005644A
MX2013005644A MX2013005644A MX2013005644A MX2013005644A MX 2013005644 A MX2013005644 A MX 2013005644A MX 2013005644 A MX2013005644 A MX 2013005644A MX 2013005644 A MX2013005644 A MX 2013005644A MX 2013005644 A MX2013005644 A MX 2013005644A
Authority
MX
Mexico
Prior art keywords
stent
myocardial injury
receptor agonist
adenosine receptor
selective adenosine
Prior art date
Application number
MX2013005644A
Other languages
English (en)
Inventor
Robert Falotico
Theodore L Parker
Original Assignee
Cordis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordis Corp filed Critical Cordis Corp
Publication of MX2013005644A publication Critical patent/MX2013005644A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se puede usar una endoprótesis u otro dispositivo médico implantable para el suministro local de un agonista selectivo del receptor de adenosina para reducir la lesión miocárdica después de un infarto agudo del miocardio; tan pronto como sea posible después de un infarto agudo del miocardio, se coloca una endoprótesis u otro dispositivo adecuado que comprende y es capaz de suministrar un agonista selectivo del receptor de adenosina en el vaso sanguíneo con la oclusión responsable de causar el infarto; una vez en posición, la endoprótesis u otro dispositivo intraluminal se despliega para eliminar la oclusión y restablecer el flujo sanguíneo al área, región o volumen de tejido específico del corazón; durante un período de tiempo el agonista selectivo del receptor de adenosina eluye de la endoprótesis u otro dispositivo hacia el flujo sanguíneo coronario corriente abajo hacia el tejido cardíaco hipóxico durante un tiempo suficiente para reducir el nivel de daño miocárdico.
MX2013005644A 2010-11-18 2011-11-09 Suministro local vascular de agonistas del receptor de adenosina a2a para reducir el daño al miocardio. MX2013005644A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41504510P 2010-11-18 2010-11-18
US12/971,037 US20120130480A1 (en) 2010-11-18 2010-12-17 Local vascular delivery of adenosine a2a receptor agonists to reduce myocardial injury
PCT/US2011/059993 WO2012067912A1 (en) 2010-11-18 2011-11-09 Local vascular delivery of adenosine a2a receptor agonists to reduce myocardial injury

Publications (1)

Publication Number Publication Date
MX2013005644A true MX2013005644A (es) 2013-07-03

Family

ID=46065054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005644A MX2013005644A (es) 2010-11-18 2011-11-09 Suministro local vascular de agonistas del receptor de adenosina a2a para reducir el daño al miocardio.

Country Status (12)

Country Link
US (1) US20120130480A1 (es)
EP (1) EP2640433A1 (es)
JP (1) JP6042342B2 (es)
KR (1) KR20130130745A (es)
CN (1) CN103209719A (es)
AU (1) AU2011329269B2 (es)
BR (1) BR112013011880B1 (es)
CA (1) CA2815382A1 (es)
IL (1) IL225642A0 (es)
MX (1) MX2013005644A (es)
RU (1) RU2013127579A (es)
WO (1) WO2012067912A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6235345B2 (ja) 2011-03-08 2017-11-22 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティドＷ．Ｌ． Ｇｏｒｅ ＆ Ａｓｓｏｃｉａｔｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ ストーマと共に使用するための医療装置
US9993251B2 (en) 2014-05-02 2018-06-12 W. L. Gore & Associates, Inc. Anastomosis devices
US11439396B2 (en) 2014-05-02 2022-09-13 W. L. Gore & Associates, Inc. Occluder and anastomosis devices
US11712230B2 (en) 2014-05-02 2023-08-01 W. L. Gore & Associates, Inc. Occluder and anastomosis devices
WO2016004441A1 (en) * 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury
US11724075B2 (en) 2017-04-18 2023-08-15 W. L. Gore & Associates, Inc. Deployment constraining sheath that enables staged deployment by device section
US12090072B2 (en) * 2018-11-13 2024-09-17 Icad Endovascular Llc Systems and methods for delivery retrievable stents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US20030077312A1 (en) * 2001-10-22 2003-04-24 Ascher Schmulewicz Coated intraluminal stents and reduction of restenosis using same
US20050220836A1 (en) * 2004-03-31 2005-10-06 Robert Falotico Drug delivery device
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
US20070212387A1 (en) * 2006-03-08 2007-09-13 Sahajanand Medical Technologies Pvt. Ltd. Coatings for implantable medical devices
WO2007134271A2 (en) * 2006-05-15 2007-11-22 Innovational Holdings Llc Method and apparatus for reducing injury from acute myocardial infarction
US20100161039A1 (en) * 2008-12-23 2010-06-24 Vipul Dave Adhesion promoting temporary mask for coated surfaces

Also Published As

Publication number Publication date
JP2014502192A (ja) 2014-01-30
WO2012067912A1 (en) 2012-05-24
KR20130130745A (ko) 2013-12-02
BR112013011880B1 (pt) 2019-01-22
CN103209719A (zh) 2013-07-17
IL225642A0 (en) 2013-06-27
JP6042342B2 (ja) 2016-12-14
BR112013011880A2 (pt) 2018-01-23
AU2011329269A1 (en) 2013-05-02
RU2013127579A (ru) 2014-12-27
AU2011329269B2 (en) 2015-01-22
US20120130480A1 (en) 2012-05-24
CA2815382A1 (en) 2012-05-24
EP2640433A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
MX2013005644A (es) Suministro local vascular de agonistas del receptor de adenosina a2a para reducir el daño al miocardio.
WO2011002239A3 (ko) 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
WO2012099910A3 (en) Ballstent device and methods of use
WO2012047803A3 (en) Distal access aspiration guide catheder
WO2014200764A8 (en) Encircling implant delivery systems and methods
NZ619320A (en) Use of guanethidine for treating hypertension by local vascular delivery
EP4424283A3 (en) System and methods for treating a bifurcation with a fully crimped stent
EP2954916A3 (en) Clinical and/or consumer techniques and devices
EP2389968A3 (en) System for cardiac surgery
WO2014168719A8 (en) Use of microparticles and endothelial cells with decellularized organs and tissues
EP4327787A3 (en) Balloon assisted endoluminal prosthesis deployment
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
MX361633B (es) Suministro local vascular de una combinacion de un agonista del receptor de adenosina a2a / inhibidor de la fosfodiesterasa para reducir la lesion del miocardio.
ZA201109415B (en) Re-establishment of blood flow in blocked human arteries by transferring nano-encapsulated drug through medical devices,designed for the same and releasing the nano-encapsulated drug in human artery with body ph
WO2007118131A3 (en) Methods and devices for reducing tissue damage after ischemic injury
WO2011089618A3 (en) Drug-eluting insert able medical device for treating acute myocardial infarction, thrombus containing lesions and saphenous- vein graft lesions
WO2008088536A3 (en) Differential drug release from a medical device
CN104352293A (zh) 一种减少晚期血栓形成的药物洗脱支架
Mount et al. Tissue-engineered cardiovascular grafts and novel applications of tissue engineering by self-assembly (tesa™)
Guidoin et al. Vascular prostheses for open surgery
CN205083715U (zh) 一种蘑菇状球囊扩张式支架
Gagnor et al. Chronic total occlusion treatment as a health insurance: Collateral recruitability and bidirectionality
CN203885672U (zh) 冠状动脉急诊治疗用双联药物洗脱支架
Refiker Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: The Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting surgery
Mauri et al. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent